PODD
Insulet Corporation
Is PODD Halal?
Insulin delivery systems manufacturer with permissible business.
What You Should Know
Insulet makes Omnipod insulin delivery systems for diabetes. Medical device business is halal, moderate debt levels within Islamic screens. Its March 31, 2026 Form 10-Q reports $2,987.2 million of assets, $948.1 million of interest-bearing debt, $480.4 million of cash, $544.7 million of receivables and $761.7 million of quarterly revenue. Debt/assets is 31.74%, liquidity/assets is 16.08%, receivables-plus-cash/assets is 34.32% and disclosed interest income is 0.64% of revenue; FTSE and Malaysia asset ratios pass, while the examined MSCI receivables-plus-cash limit is exceeded.
⚠️ Concerns
- •Receivables-plus-cash/assets 34.32% exceeds the examined MSCI limit
- •Moderate interest-bearing debt
- •Voluntary device corrections and product quality
- •Interest income
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
948.1 / 2,987.2
480.4 / 2,987.2
1,025.1 / 2,987.2
4.9 / 761.7
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 31.74%, liquidity/assets is 16.08%, receivables-plus-cash/assets is 34.32% and disclosed interest income is 0.64% of revenue; examined FTSE financial ratios pass while activity remains incomplete.
- Financial
- Fails
- Overall
- Fails
Receivables-plus-cash/assets is 34.32%, above the examined MSCI 33.33% limit; debt/assets and liquidity/assets are 31.74% and 16.08%.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets and liquidity/assets pass the examined Malaysia limits; this is a calculation against SAC ratios, not an official classification, and activity remains incomplete.
- Financial
- Not calculated
- Overall
- Incomplete
A properly licensed and reproducible historical market-cap series is not stored; method-specific filing-based results remain documented.
Business-activity disclosure
Insulet develops and sells tubeless insulin-delivery systems and related medical devices. The core medical-device activity is generally permissible.
Limitation: The filing does not provide a universal prohibited-activity revenue numerator across Omnipod products, drug-delivery partnerships and customer use.
Purification
Insulet discloses $4.9 million of interest income, but does not provide a complete prohibited-activity numerator or scholar-approved purification percentage.
Inputs, assumptions and primary sources
- Amounts are USD millions from Insulet's March 31, 2026 Form 10-Q.
- Interest-bearing debt is $18.6 million of current debt plus $929.5 million of long-term debt, including the disclosed finance-lease obligation; operating lease liabilities are excluded.
- Cash and cash equivalents are $480.4 million and no separate interest-bearing securities balance is identified for this screen.
- Accounts receivable are $544.7 million, quarterly revenue is $761.7 million and disclosed interest income is $4.9 million.
- Insulin-delivery and medical-device products are generally permissible, while product quality, recalls, drug-delivery partnerships and customer use require qualitative review.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →